Riskpilot← Back to searchSign inGet full accessBifos AB
ABDissolvedOrg 5565757712Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19990 employees
Revenue 2022
SEK 0
EBITDA margin
—
+62% vs 2021
Equity ratio
100.0%
Financial strength
Net profit 2022
SEK -198K
+64% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -204K | +62% |
| Net profit | SEK -198K | +64% |
| Total assets | SEK 594K | -85% |
| Equity | SEK 594K | -25% |
| Employees | 0 | — |
Legal name
Bifos AB
Org number
5565757712
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 september 1999
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall utveckla, sälja och marknadsföra medicintekniska produkter samt bedriva därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 13 090 | 15 699 | 17 991 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 12 682 | 15 139 | 17 371 | −536 | −204 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 12 682 | 15 139 | 17 371 | −536 | −204 |
| Net financials | 23 355 | 4 175 | 2 083 | −10 | 7 |
| Profit before tax | 27 026 | 28 325 | 19 453 | −546 | −198 |
| Tax | −5 947 | −6 144 | −4 172 | −0 | −0 |
| Net profit | 21 079 | 22 181 | 15 281 | −546 | −198 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 95 821 | 49 500 | 23 765 | 3 978 | 594 |
| Equity | 82 337 | 42 481 | 19 638 | 791 | 594 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 472 | 7 019 | 4 127 | 3 187 | 0 |
| Total debt | 4 472 | 7 019 | 4 127 | 3 187 | — |
EBITDA margin
-20400000.0%
This company
15.8%
Market median
-129114024% vs market
20182022
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20182022
Return on equity
-33.3%
This company
18.4%
Market median
-281% vs market
20182022
Net profit margin
-19800000.0%
This company
8.1%
Market median
-244444544% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
CD Authorized Recipient of Service | Authorized Recipient of Service | 2022 – 2022 |
AG Chief Auditor | Chief Auditor | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Chairman | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bifos AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl David Aversten | Authorized Recipient of Service | 0 companies |
| Anna Gabriella Hermansson | Chief Auditor | 0 companies |
| Clas Petter Bengtsson | Board of Directors | 0 companies |
| Lena Marianne Bengtsson | Deputy Board Member | 0 companies |
| Sharon Cynthia McNally | Chairman | 0 companies |
| Mai Brit Blom | Board of Directors | 0 companies |